A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Efficacy, Safety, and Tolerability of Carbavance (Meropenem/Vaborbactam) Compared to Piperacillin/Tazobactam in the Treatment of cUTIs, Including AP, in Adults

Trial Profile

A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Efficacy, Safety, and Tolerability of Carbavance (Meropenem/Vaborbactam) Compared to Piperacillin/Tazobactam in the Treatment of cUTIs, Including AP, in Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Meropenem/vaborbactam (Primary) ; Levofloxacin; Piperacillin/tazobactam
  • Indications Pyelonephritis; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms TANGO 1
  • Sponsors Rempex Pharmaceuticals
  • Most Recent Events

    • 05 Oct 2017 Results presented in The Medicines Company media release.
    • 28 Sep 2017 According to The Medicines Company media release, data will be presented at IDWeek 2017.
    • 30 Aug 2017 According to The Medicines Company media release, based on the data from trial, the U.S. FDA has approved VABOMERE (meropenem and vaborbactam) for injection for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis, caused by designated susceptible Enterobacteriaceae Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae species complex.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top